Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10548
Country/Region: Ethiopia
Year: 2015
Main Partner: Jimma University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $600,000 Additional Pipeline Funding: $20,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Pediatric Care and Support (PDCS) $25,000
Health Systems Strengthening (OHSS) $140,000
Sexual Prevention: Other Sexual Prevention (HVOP) $25,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $30,000
Treatment: Adult Treatment (HTXS) $320,000
Treatment: Pediatric Treatment (PDTX) $60,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HRH_PRE By Graduates: Doctors 2016 172
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2016 172
HRH_PRE Sum of Graduates disaggregates 2016 172
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 145
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 137
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 89
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 48
PMTCT_ARV Sum of New and Current disaggregates 2016 137
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 104
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 26
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 130
PMTCT_EID Sum of Infant Age disaggregates 2016 130
PMTCT_STAT By: Known positives at entry 2016 102
PMTCT_STAT By: Number of new positives identified 2016 44
PMTCT_STAT Number of new ANC and L&D clients 2016 5,322
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 5,056
PMTCT_STAT Sum of Positives Status disaggregates 2016 146
TX_CURR Age/Sex: <1 Female 2016 16
TX_CURR Age/Sex: <1 Male 2016 19
TX_CURR Age/Sex: 1-4 Female 2016 58
TX_CURR Age/Sex: 1-4 Male 2016 66
TX_CURR Age/Sex: 5-14 Female 2016 117
TX_CURR Age/Sex: 5-14 Male 2016 113
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 3,593
TX_CURR Sum of age/sex disaggregates 2016 3,593
TX_NEW By Age/Sex: <1 Female 2016 5
TX_NEW By Age/Sex: <1 Male 2016 5
TX_NEW By Age/Sex: 1-4 Female 2016 13
TX_NEW By Age/Sex: 1-4 Male 2016 16
TX_NEW By Age/Sex: 10-14 Female 2016 9
TX_NEW By Age/Sex: 10-14 Male 2016 9
TX_NEW By Age/Sex: 15-19 Female 2016 8
TX_NEW By Age/Sex: 15-19 Male 2016 3
TX_NEW By Age/Sex: 20-24 Female 2016 60
TX_NEW By Age/Sex: 20-24 Male 2016 12
TX_NEW By Age/Sex: 25-49 Female 2016 302
TX_NEW By Age/Sex: 25-49 Male 2016 170
TX_NEW By Age/Sex: 5-9 Female 2016 15
TX_NEW By Age/Sex: 5-9 Male 2016 18
TX_NEW By Age/Sex: 50+ Female 2016 7
TX_NEW By Age/Sex: 50+ Male 2016 20
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 672
TX_NEW Sum of Age/Sex disaggregates 2016 672
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 395
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 465
Cross Cutting Budget Categories and Known Amounts Total: $113,200
Condoms: Policy, Tools, and Services $3,100
Gender: Gender Based Violence (GBV) $3,100
Post GBV Care
Implementation
Capacity building
Human Resources for Health $62,000
Motor Vehicles: Purchased $45,000